Dexamethasone reduces serum level of IL-17 in Bleomycin-A5-induced rats model of pulmonary fibrosis
Source abstract
Abstract
BACKGROUND: Pulmonary fibrosis is a chronic progressive disease with limited therapeutic options and inflammatory cytokines play important roles in the pathogenesis of pulmonary fibrosis. MATERIAL AND METHOD: Here, we investigated the changes of TGF-β1, IL-8, and IL-17 in the serum of bleomycin-A5-induced rats model of pulmonary fibrosis. 120 healthy male Wistar rats were randomly divided into three groups, the control group (n = 30), the model group (n = 45) and the dexamethasone (DEX) group (n = 45). The rats of both model group and DEX group were injected with Bleomycin-A5 (5 mg/kg) through tracheofistulization to induce pulmonary fibrosis, while the rats of the control group were injected with equivalent physiological saline. After operation, DEX (4 mg/kg) was given to the DEX group rats intraperitoneally once a day. Equivalent saline was administered to rats of both the control group and the model group. RESULTS: IL-8, and IL-17 were significantly increased after bleomycin-A5 treatment, especially on the 14th day (p < .01). There was no significant difference between model group and DEX group in the serum level of TGF-β1 and IL-8, but DEX treatment significantly reduce serum IL-17 level (p < .01). CONCLUSIONS: DEX protect bleomycin-A5-induced pulmonary fibrosis in rats through reduced the level of IL-17 in serum.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Cystic Fibrosis Research Advances · Lung Cancer Treatments and Mutations
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, China;
Department of Respiratory Medicine, Liaocheng People's Hospital, Liaocheng, China;
Department of Respiratory Medicine, Yuebei People’s Hospital, Shaoguan, China;
Department of tubercular Medicine, Shandong Chest Hospital, Jinan, China;
Department of Pharmacy, Shandong Provincial Hospital, Jinan, China
References (23)
Show source-provided references
1. Kaur G · Artif Cells Nanomed Biotechnol · 2011 · 2 · 75
2. 10.1172/JCI3148710.1172/JCI31487 ↗
3. Zisman DA · Methods Mol Med · 2005 · 117 · 3
4. 10.1016/j.redox.2015.09.00910.1016/j.redox.2015.09.009 ↗
5. 10.1152/ajplung.00258.201210.1152/ajplung.00258.2012 ↗
6. 10.1056/NEJMra00320010.1056/NEJMra003200 ↗
7. 10.3904/kjim.2014.29.3.28110.3904/kjim.2014.29.3.281 ↗
8. 10.18632/oncotarget.840910.18632/oncotarget.8409 ↗
9. 10.4110/in.2015.15.3.14210.4110/in.2015.15.3.142 ↗
10. Rice KM · Artif Cells Nanomed Biotechnol · 2015 · 03 · 1909
11. 10.1172/JCI1256810.1172/JCI12568 ↗
12. 10.1038/mi.2008.8510.1038/mi.2008.85 ↗
13. 10.1016/S0083-6729(06)74019-510.1016/S0083-6729(06)74019-5 ↗
14. 10.1006/cyto.1997.024010.1006/cyto.1997.0240 ↗
15. Chen XL · Acta Pharmacol Sin · 2003 · 24 · 697
16. Shi K · Int J Clin Exp Med · 2014 · 7 · 2645
17. Adamson IY · Am J Pathol · 1974 · 77 · 185
18. Szapiel SV · Am Rev Respir Dis · 1979 · 120 · 893
19. 10.1378/chest.13-069310.1378/chest.13-0693 ↗
20. 10.1067/mai.2001.11792910.1067/mai.2001.117929 ↗
21. 10.1182/blood-2007-05-09107410.1182/blood-2007-05-091074 ↗
22. Rath G · Artif Cells Nanomed Biotechnol · 2015 · 18 · 1783
23. 10.1136/thoraxjnl-2013-20330710.1136/thoraxjnl-2013-203307 ↗